Document is current

Article History

Received: 13 September 2025

Accepted: 24 October 2025

First Online: 7 November 2025

Declarations

:

: Marta Trigo-Rodríguez has received payment or honoraria from Tillots for lectures or speakers bureaus. Esperanza Merino has received payment or honoraria from MSD and Tillots for lectures or speakers bureaus. Nicolás Merchante has received payment or honoraria from Tillots, Merck, Sharp, and Dome for lectures or speakers bureaus. All other authors (Miguel Rodríguez-Fernández, Rocio Herrero, Pilar González-De-La-Aleja, María Dolores Valverde-Fredet, María-Paz Ventero, Livia Giner, Ana Isabel Aller-García, Héctor Pinargote-Celorio, Reinaldo Espíndola-Gómez, Mónica Parra, Pedro Martínez Pérez-Crespo, José-Manuel Ramos-Rincón, Antonio Fernández-Pevida, Joaquín Lanz-García, Eva León, Lucía Valiente-De-Santis, Juan E. Corzo, and Juan-Carlos Rodríguez) have nothing to declare.

: This study was designed and performed according to the Declaration of Helsinki and was approved by HUV Ethics Committee (ref. no. 1254-N-20). Following this approval, all participating centers were formally notified and adhered to the study protocol on the basis of the favorable evaluation from the coordinating center’s ethics committee. With respect to informed consent, a waiver was granted. This was based on the consideration that the intervention implemented—namely, the introduction of a specific clinical pathway for CDI management—was intended to become part of the standard clinical practice routinely conducted by our institutional ASP team dedicated to CDI. Therefore, it was not deemed necessary to obtain individual patient consent.